Profound Medical Earnings Call Maps Path to Profit
Profound Medical ((TSE:PRN)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Profound Medical’s latest earnings call struck a cautiously optimistic tone, as strong top-line growth and a clearer roadmap to profitability overshadowed widening losses and softer margins. Management emphasized accelerating adoption of its TULSA‑PRO platform, improving reimbursement tailwinds, and disciplined cash management, while acknowledging that utilization and operating leverage still need to catch up.
Robust Revenue Growth but Losses Still Mount
Profound posted Q4 2025 revenue of $6.0 million, up 43% year over year from $4.2 million, with $2.3 million from recurring revenue and $3.7 million from capital sales. However, the net loss widened to $8.2 million, or $0.27 per share, from $4.9 million, reflecting the cost of building out its commercial footprint.
Installed Base Expands with Growing Sales Pipeline
The company ended 2025 with 78 TULSA‑PRO sites and cited a qualified pipeline of roughly 110 systems, up from 97 previously, showing rising commercial interest. Management expects about 120 installs by the end of 2026 and is ultimately targeting a 200‑site installed base to support its profitability goals.
CAPTAIN Trial Readout to Elevate Clinical Profile
Profound has completed enrollment in its CAPTAIN randomized multicenter trial, designed to compare TULSA against robotic prostatectomy in a Level 1 setting. Key six‑month safety and quality‑of‑life endpoints, plus 90‑day perioperative data, will be presented at the EAU meeting in mid‑March, potentially providing a major clinical validation milestone.
Reimbursement Tailwinds Strengthen TULSA Economics
The reimbursement backdrop continues to improve, with 2026 Medicare national average payment for TULSA procedures set at $13,479, above robotic surgery at $10,860 and focal therapies at $9,672. In‑bore MR biopsy reimbursement is about $5,500 versus roughly $3,500 for MR‑registered ultrasound, a 57% premium that supports the economics of MRI‑guided care.
Quantified Path to Profitability at Scale
Management outlined a path to profitability at around $80–85 million in annual revenue, assuming gross margins above 70%. Their model envisions 200 TULSA sites performing 50 procedures each per year, generating $55 million in procedural revenue, roughly $10 million from service, and near $20 million from capital sales of about 40 systems.
Recurring Revenue Engine Built Around Per‑Procedure Fees
The company reiterated its focus on building a recurring revenue model anchored in a fixed disposable price of $5,500 per TULSA procedure. Over time, management expects more than 70% of total revenue to come from recurring sources, making utilization per site a critical driver of long‑term financial performance.
BPH Module Aims to Triple Addressable Market
Profound highlighted its new TULSA‑AI volume‑reduction module for benign prostatic hyperplasia, which cuts procedure times to roughly 60–90 minutes and enables stacked treatment days. Management believes this innovation could add about 400,000 annual patients to its addressable market, effectively tripling the company’s prior TAM assumptions.
Sonalleve Platform Adds Optionality Beyond Prostate
The company’s Sonalleve platform has around 10 devices in operation internationally and has been used to treat more than 4,000 women with adenomyosis or fibroids. Profound is pursuing an FDA strategy and exploring recurring revenue models for Sonalleve, which could diversify growth beyond TULSA and pure capital sales.
Cash Burn Improves as Balance Sheet Supports Scaling
Profound closed 2025 with $59.7 million in cash, while quarterly cash burn improved from more than $10 million in the first half to about $8 million in Q3 and under $6.5 million in Q4. Management framed this trend as evidence of tightening financial discipline and expects burn to continue declining as revenue scales toward cash‑flow breakeven.
Margins and Operating Spend Remain Pressure Points
Gross margin slipped to 67% in Q4 2025 from 71% a year earlier, pressured by product mix and introductory international distributor pricing. Operating expenses for R&D and SG&A held roughly flat at $11.4 million versus $11.3 million, still heavy relative to the current revenue base and contributing to the larger quarterly loss.
Capital Mix Volatility and Underutilized Sites
Management cautioned that capital equipment sales remain lumpy, with Q4 skewed toward one‑time hardware and expecting a 40–60% capital versus recurring mix in early years, adding revenue volatility. Average procedures per site are implied at only 20–25 annually, well below the modeled 50, though some mature centers exceed 100 procedures and are cited as proof points.
International Pricing and Early BPH Adoption Limit Near‑Term Upside
Lower introductory pricing for new international distributors in markets such as Saudi Arabia and Australia weighed on margins, a trade‑off the company is accepting to accelerate adoption. Meanwhile, BPH volumes remain modest despite regulatory clearance, as earlier TULSA procedures were longer than competing options, which the new AI module is intended to fix over time.
Guidance Signals Aggressive Growth and Profit Focus
Looking ahead, management is guiding to “profitable growth,” calling for high double‑digit to low triple‑digit revenue expansion in 2026 as the TULSA install base rises toward about 120 sites. They reaffirmed that profitability should be achievable around $80–85 million of revenue with 70%‑plus gross margins, supported by rising utilization, expanding BPH adoption, and a declining cash burn trajectory.
Profound Medical’s earnings call painted a picture of a company in transition from clinical proof to commercial scale, with strong growth, rich reimbursement, and a credible profitability roadmap. Investors will now watch execution on utilization, BPH ramp‑up, and CAPTAIN data as key catalysts that could validate the bullish long‑term thesis despite near‑term volatility and losses.
